United States Nephrotic Syndrome Drugs Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The global nephrotic syndrome drugs market reached US$ 423.7 million in 2023 and is expected to reach US$ 645.3 million by 2030, growing with a CAGR of 5.4% during the forecast period 2024-2031.

Recent Mergers and Acquisitions:

United States:

✅ In June 2025, Biogen initiated a Phase 3 study of felzartamab for the treatment of primary membranous nephropathy, a common cause of nephrotic syndrome. This trial aims to evaluate the efficacy and safety of felzartamab compared to tacrolimus in adults.

✅ In May 2025, the FDA accepted a supplemental New Drug Application (sNDA) for Travere Therapeutics' FILSPARI® (sparsentan) targeting focal segmental glomerulosclerosis (FSGS). If approved, it would be the first FDA-approved treatment for this rare kidney condition.

✅ In April 2025, Novartis acquired Regulus Therapeutics for up to $1.7 billion, gaining access to an experimental RNA-based drug targeting a life-threatening kidney disease.

✅ In March 2025, scPharmaceuticals received FDA approval for FUROSCIX® (furosemide injection) to treat heart failure patients with fluid overload. This approval marks a significant advancement in outpatient diuretic therapy.

Japan:

✅ In July 2025, Chugai Pharmaceutical announced the development of obinutuzumab (GA101) for pediatric nephrotic syndrome, currently in Phase III trials. This collaboration with Nippon Shinyaku aims to address intractable and rare diseases.

✅ In March 2025, Chugai Pharmaceutical and Zenyaku Kogyo received approval from Japan's Ministry of Health, Labour and Welfare for Rituxan® (rituximab) to treat frequently relapsing or steroid-dependent nephrotic syndrome in children. This approval expands treatment options for challenging cases.

✅ In November 2024, Mitsui Chemicals invested in Rege Nephro, a clinical-stage drug discovery startup focused on kidney diseases. This investment supports the development of novel treatments utilizing iPS cell technology.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nephrotic-syndrome-drugs-market?sb

Nephrotic Syndrome Drugs are medications used to manage nephrotic syndrome, a kidney disorder characterized by excessive protein loss in urine, swelling, and low blood protein levels. Treatments include corticosteroids, immunosuppressants, diuretics, and ACE inhibitors or ARBs to reduce symptoms, prevent complications, and protect kidney function.

Key Players:

=> Aldeyra Therapeutics, Inc., Asahi Kasei Pharma Corp., Manus Aktteva Biopharma LLP, Dr. Reddy's Laboratories, Century Pharmaceuticals Limited, Viatris Mylan, Alembic Pharmaceuticals, Salvavidas Pharmaceutical Pvt. Ltd., Rosemont Pharmaceuticals, Hoffmann-La Roche among others.

Growth Forecast Projected:

The Global Nephrotic Syndrome Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Nephrotic Syndrome Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nephrotic-syndrome-drugs-market

Key Segments:

➥ By Type: Primary Nephrotic Syndrome Drugs, Secondary Nephrotic Syndrome

➥ By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Diuretics, Statins, Blood Coagulants, Corticosteroids, Others

➥ By Treatment: Proteinuria, Hypoalbuminemia

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Nephrotic Syndrome Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Nephrotic Syndrome Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Nephrotic Syndrome Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nephrotic-syndrome-drugs-market?sb

FAQ

What is the current size of the Nephrotic Syndrome Drugs Market?

A: In 2023, the Nephrotic Syndrome Drugs Market was valued at US$ 423.7 million , reflecting its strong industry presence.

Q2: How large is the Nephrotic Syndrome Drugs Market expected to be by 2030?

A: By 2030, industry forecasts suggest the Nephrotic Syndrome Drugs Market will grow to around US$ 645.3 million, demonstrating significant expansion.

Q3: What is the growth rate of the Nephrotic Syndrome Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.4% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.